Nanjing Jiangyuan Andico Positron Research and Development Co., Ltd

In 2006, Nanjing Jiangyuan Andico Positron Research and Development Co., Ltd. (referred to as Dongcheng Andico) was established with the development direction of "Early Diagnosis · Precision Therapy". Its mission is to promote the popularization and application of non powered civilian nuclear technology in the medical field, and to build an industry recognized excellent enterprise, making special contributions to promoting people's health.

Dongcheng Andike is a leading enterprise in the networked production and distribution of radioactive drugs in China, serving over 95% of the country's population; 18F-FDG accounts for half of the domestic market share among approved drugs for marketing; Medical cyclotrons have sold over 100 units.

Dongcheng Andike is a nuclear medical innovation technology enterprise, a high-tech enterprise, a technology-based gazelle enterprise, and a provincial specialized, refined, and new enterprise; Provincial enterprise technology center and graduate workstation. In 2018, it was acquired by Dongcheng Pharmaceutical (SZ002675) and became a wholly-owned subsidiary of Dongcheng Pharmaceutical.